GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Lyell Immunopharma, Inc.; Novartis; Sanofi SA; Surface Oncology; Progentec Diagnostics, Inc.; Alector, Inc.; and CureVac AG., as well as strategic partnership with IDEAYA Biosciences, Inc. and Vir Biotechnology, Inc. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.
Analysts Set New Price Targets
Several research firms have recently commented on GSK. Citigroup reissued a "neutral" rating on shares of GSK in a report on Thursday, July 21st. UBS Group lowered their target price on shares of GSK from GBX 1,876 ($22.67) to GBX 1,850 ($22.35) in a report on Wednesday, July 20th. Morgan Stanley reissued an "equal weight" rating on shares of GSK in a report on Friday, August 5th. TheStreet raised shares of GSK from a "c+" rating to an "a-" rating in a report on Friday, July 22nd. Finally, Credit Suisse Group boosted their target price on shares of GSK from GBX 1,400 ($16.92) to GBX 1,600 ($19.33) in a report on Friday, July 15th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating, one has given a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, GSK has a consensus rating of "Hold" and a consensus target price of $1,787.50.
GSK Price Performance
GSK Stock opened at $40.03 on Wednesday. The company has a market cap of $81.41 billion, a price-to-earnings ratio of 13.26, a PEG ratio of 1.45 and a beta of 0.46. The firm's fifty day moving average is $42.41 and its 200 day moving average is $43.38. The company has a quick ratio of 1.31, a current ratio of 1.43 and a debt-to-equity ratio of 0.83. GSK has a 52-week low of $37.80 and a 52-week high of $46.97.
GSK Increases Dividend
The firm also recently declared a quarterly dividend, which will be paid on Thursday, October 6th. Investors of record on Friday, August 19th will be paid a dividend of $0.383 per share. This is an increase from GSK's previous quarterly dividend of $0.35. The ex-dividend date is Thursday, August 18th. This represents a $1.53 dividend on an annualized basis and a yield of 3.83%. GSK's dividend payout ratio is presently 55.30%.